Open Access

FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression

  • Authors:
    • Jiafeng Tong
    • Ying Shen
    • Xi Chen
    • Renjie Wang
    • Ye Hu
    • Xu Zhang
    • Zhenghua Zhang
    • Li Han
  • View Affiliations

  • Published online on: August 2, 2019     https://doi.org/10.3892/or.2019.7259
  • Pages: 1404-1412
  • Copyright: © Tong et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Colorectal cancer (CRC), a commonly occurring malignant tumor in the gastrointestinal tract, is the third leading cause of cancer‑related deaths worldwide. FK506‑binding proteins (FKBPs) comprise an immunophilin family that are involved in the carcinogenesis, progression and chemoresistance of cancers, including CRC. FKBP3 (also known as FKBP25) is a nuclear protein that is a member of the FKBP family and is correlated with the activity of histone deacetylase 2 (HDAC2). However, the role of FKBP3 and HDAC2 in oxaliplatin resistance in CRC and the potential molecular mechanisms are still poorly understood. In the present study, the expression of FKBP3, HDAC2 and related‑genes was detected by real‑time PCR and western blot analysis. Furthermore, cell apoptosis was detected by flow cytometry (FCM). We found high expression of FKBP3 and HDAC2 in CRC tissues. In vitro, primary CRC cells with high expression of FKBP3 and HDAC2 were insensitive to oxaliplatin. Downregulation of FKBP3 significantly increased the sensitivity of primary CRC cells to oxaliplatin, reduced expression of HDAC2, permeability glycoprotein (P‑gp) and phosphorylated AKT (p‑AKT), and increased expression of phosphatase and tensin homolog (PTEN) and cleaved caspase‑3. Accordingly, upregulation of FKBP3 had the opposite effect. Furthermore, downregulation of HDAC2 significantly counteracted FKBP3‑induced oxaliplatin resistance in CRC cells. Our data revealed that oxaliplatin resistance in CRC cells is positively associated with FKBP3 and HDAC2 expression, and FKBP3 downregulation could attenuate oxaliplatin resistance in CRC cells by reducing HDAC2 expression and possibly through regulation of the PTEN/AKT pathway.

References

1 

Ung L, Lam KY, Morris DL and Chua TC: Tissue-based biomarkers predicting outcomes in metastatic colorectal cancer: a review. Clin Transl Oncol. 16:425–435. 2014. View Article : Google Scholar : PubMed/NCBI

2 

Sostres C, Gargallo CJ and Lanas A: Aspirin, cyclooxygenase inhibition and colorectal cancer. World J Gastrointest Pharmacol Ther. 5:40–49. 2014. View Article : Google Scholar : PubMed/NCBI

3 

Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI

4 

Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ and He J: Cancer statistics in China, 2015. CA Cancer J Clin. 66:115–132. 2016. View Article : Google Scholar : PubMed/NCBI

5 

Overman MJ, Morris V, Moinova H, Manyam G, Ensor J, Lee MS, Eng C, Kee B, Fogelman D, Shroff RT, et al: Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: Evaluation of circulating methylated vimentin. Oncotarget. 7:67495–67506. 2016. View Article : Google Scholar : PubMed/NCBI

6 

Meyerhardt JA and Mayer RJ: Systemic therapy for colorectal cancer. N Engl J Med. 352:476–487. 2005. View Article : Google Scholar : PubMed/NCBI

7 

Kelland L: The resurgence of platinum-based cancer chemotherapy. Nat Rev Cancer. 7:573–584. 2007. View Article : Google Scholar : PubMed/NCBI

8 

Koul D, Shen R, Bergh S, Sheng X, Shishodia S, Lafortune TA, Lu Y, de Groot JF, Mills GB and Yung WK: Inhibition of Akt survival pathway by a small-molecule inhibitor in human glioblastoma. Mol Cancer Ther. 5:637–644. 2006. View Article : Google Scholar : PubMed/NCBI

9 

Xiong F and Chen J: Effect of miR-3651 on proliferation, apoptosis and expression of PTEN in colon cancer cells. Chin Clin Oncol. 22:865–868. 2017.

10 

Liang YF, Jian-Bo R, Wang LM, Chen C, Kang DP, Lin BH, Chai XX, Zeng JC and Pathology DO: Expression and clinical significance of PTEN in colon cancer. China Tropical Med. 15:966–969. 2015.

11 

He C, Dong X, Zhai B, Jiang X, Dong D, Li B, Jiang H, Xu S and Sun X: MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway. Oncotarget. 6:28867–28881. 2015. View Article : Google Scholar : PubMed/NCBI

12 

Li J, Zhang Y, Zhao J, Kong F and Chen Y: Overexpression of miR-22 reverses paclitaxel-induced chemoresistance through activation of PTEN signaling in p53-mutated colon cancer cells. Mol Cell Biochem. 357:31–38. 2011. View Article : Google Scholar : PubMed/NCBI

13 

Solassol J, Mange A and Maudelonde T: FKBP family proteins as promising new biomarkers for cancer. Curr Opin Pharmacol. 11:320–325. 2011. View Article : Google Scholar : PubMed/NCBI

14 

Mukaide H, Adachi Y, Taketani S, Iwasaki M, Koi-Kekiriyama N, Shigematsu A, Shi M, Yanai S, Yoshioka K, Kamiyama Y and Ikehara S: FKBP51 expressed by both normal epithelial cells and adenocarcinoma of colon suppresses proliferation of colorectal adenocarcinoma. Cancer Invest. 26:385–390. 2008. View Article : Google Scholar : PubMed/NCBI

15 

Li L, Lou Z and Wang L: The role of FKBP5 in cancer aetiology and chemoresistance. Br J Cancer. 104:19–23. 2011. View Article : Google Scholar : PubMed/NCBI

16 

Luo K, Li Y, Yin Y, Lei L, Wu C, Chen Y, Nowsheen S, Qi H, Zhang L, Lou Z and Yuan J: USP49 negatively regulates tumorigenesis and chemoresistance through FKBP51-AKT signaling. EMBO J. 36:1434–1446. 2017. View Article : Google Scholar : PubMed/NCBI

17 

Ochocka AM, Kampanis P, Nicol S, Allende-Vega N, Cox M, Marcar L, Milne D, Fuller-Pace F and Meek D: FKBP25, a novel regulator of the p53 pathway, induces the degradation of MDM2 and activation of p53. FEBS Lett. 583:621–626. 2009. View Article : Google Scholar : PubMed/NCBI

18 

Yang WM, Yao YL and Seto E: The FK506-binding protein 25 functionally associates with histone deacetylases and with transcription factor YY1. EMBO J. 20:4814–4825. 2001. View Article : Google Scholar : PubMed/NCBI

19 

Oiso H, Furukawa N, Suefuji M, Shimoda S, Ito A, Furumai R, Nakagawa J, Yoshida M, Nishino N and Araki E: The role of class I histone deacetylase (HDAC) on gluconeogenesis in liver. Biochem Biophys Res Commun. 404:166–172. 2011. View Article : Google Scholar : PubMed/NCBI

20 

Jeong JB and Lee SH: Protocatechualdehyde possesses anti- cancer activity through downregulating cyclin D1 and HDAC2 in human colorectal cancer cells. Biochem Biophys Res Commun. 430:381–386. 2013. View Article : Google Scholar : PubMed/NCBI

21 

Zhang H, Zhao B, Huang C, Meng XM, Bian EB and Li J: Melittin restores PTEN expression by down-regulating HDAC2 in human hepatocelluar carcinoma HepG2 cells. PLoS One. 9:e955202014. View Article : Google Scholar : PubMed/NCBI

22 

Zhu W, Li Z, Xiong L, Yu X, Chen X and Lin Q: FKBP3 promotes proliferation of non-small cell lung cancer cells through regulating Sp1/HDAC2/p27. Theranostics. 7:3078–3089. 2017. View Article : Google Scholar : PubMed/NCBI

23 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

24 

Hong JY, Kang B, Kim A, Hwang S, Ahn J, Lee S, Kim J, Park JH and Cheon DS: Development of a highly sensitive real-time one step RT-PCR combined complementary locked primer technology and conjugated minor groove binder probe. Virol J. 8:3302011. View Article : Google Scholar : PubMed/NCBI

25 

Xiong H, Hong J, Du W, Lin YW, Ren LL, Wang YC, Su WY, Wang JL, Cui Y, Wang ZH and Fang JY: Roles of STAT3 and ZEB1 proteins in E-cadherin down-regulation and human colorectal cancer epithelial-mesenchymal transition. J Biol Chem. 287:5819–5832. 2012. View Article : Google Scholar : PubMed/NCBI

26 

Virag P, Brie I, Fischer-Fodor E, Perde-Schrepler M, Tatomir C, Balacescu O, Irimie A and Postescu ID: Assessment of cytotoxicity, apoptosis and DNA damages in Colo320 colorectal cancer cells selected for oxaliplatin resistance. Cell Biochem Funct. 29:351–355. 2011. View Article : Google Scholar : PubMed/NCBI

27 

Cohen GM: Caspases: The executioners of apoptosis. Biochem J. 326:1–16. 1997. View Article : Google Scholar : PubMed/NCBI

28 

Gao G and Dou QP: G(1) phase-dependent expression of bcl-2 mRNA and protein correlates with chemoresistance of human cancer cells. Mol Pharmacol. 58:1001–1010. 2000. View Article : Google Scholar : PubMed/NCBI

29 

Lee MS, Jeong MH, Lee HW, Han HJ, Ko A, Hewitt SM, Kim JH, Chun KH, Chung JY, Lee C, et al: PI3K/AKT activation induces PTEN ubiquitination and destabilization accelerating tumourigenesis. Nat Commun. 6:77692015. View Article : Google Scholar : PubMed/NCBI

30 

Salmena L, Carracedo A and Pandolfi PP: Tenets of PTEN tumor suppression. Cell. 133:403–414. 2008. View Article : Google Scholar : PubMed/NCBI

31 

Davies MA, Lu Y, Sano T, Fang X, Tang P, Lapushin R, Koul D, Bookstein R, Stokoe D, Yung WK, et al: Adenoviral transgene expression of MMAC/PTEN in human glioma cells inhibits akt activation and induces anoikis. Cancer Res. 58:5285–5290. 1998.PubMed/NCBI

32 

Mehrian-Shai R, Chen CD, Shi T, Horvath S, Nelson SF, Reichardt JK and Sawyers CL: Insulin growth factor-binding protein 2 is a candidate biomarker for PTEN status and PI3K/Akt pathway activation in glioblastoma and prostate cancer. Proc Natl Acad Sci USA. 104:5563–5568. 2007. View Article : Google Scholar : PubMed/NCBI

33 

Choi BH and Yoon HS: FKBP38-Bcl-2 interaction: A novel link to chemoresistance. Curr Opin Pharmacol. 11:354–359. 2011. View Article : Google Scholar : PubMed/NCBI

34 

Ma D, Bai X, Zou H, Lai Y and Jiang Y: Rheb GTPase controls apoptosis by regulating interaction of FKBP38 with Bcl-2 and Bcl-XL. J Biol Chem. 285:8621–8627. 2010. View Article : Google Scholar : PubMed/NCBI

35 

Krämer OH, Knauer SK, Zimmermann D, Stauber RH and Heinzel T: Histone deacetylase inhibitors and hydroxyurea modulate the cell cycle and cooperatively induce apoptosis. Oncogene. 27:732–740. 2008. View Article : Google Scholar : PubMed/NCBI

36 

Jung KH, Noh JH, Kim JK, Eun JW, Bae HJ, Xie HJ, Chang YG, Kim MG, Park H, Lee JY and Nam SW: HDAC2 overexpression confers oncogenic potential to human lung cancer cells by deregulating expression of apoptosis and cell cycle proteins. J Cell Biochem. 113:2167–2177. 2012. View Article : Google Scholar : PubMed/NCBI

37 

Wang X, Taplick J, Geva N and Oren M: Inhibition of p53 degradation by Mdm2 acetylation. FEBS Lett. 561:195–201. 2004. View Article : Google Scholar : PubMed/NCBI

38 

Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C and González-Barón M: PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30:193–204. 2004. View Article : Google Scholar : PubMed/NCBI

39 

Gan YH and Zhang S: PTEN/AKT pathway involved in histone deacetylases inhibitor induced cell growth inhibition and apoptosis of oral squamous cell carcinoma cells. Oral Oncol. 45:e150–e154. 2009. View Article : Google Scholar : PubMed/NCBI

40 

Song MS, Salmena L and Pandolfi PP: The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 13:283–296. 2012. View Article : Google Scholar : PubMed/NCBI

41 

van Echten-Deckert G, Zschoche A, Bär T, Schmidt RR, Raths A, Heinemann T and Sandhoff K: cis-4-Methylsphingosine decreases sphingolipid biosynthesis by specifically interfering with serine palmitoyltransferase activity in primary cultured neurons. J Biol Chem. 272:15825–15833. 1997. View Article : Google Scholar : PubMed/NCBI

42 

Nemoto S, Nakamura M, Osawa Y, Kono S, Itoh Y, Okano Y, Murate T, Hara A, Ueda H, Nozawa Y and Banno Y: Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. J Biol Chem. 284:10422–10432. 2009. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

October 2019
Volume 42 Issue 4

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Tong, J., Shen, Y., Chen, X., Wang, R., Hu, Y., Zhang, X. ... Han, L. (2019). FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression. Oncology Reports, 42, 1404-1412. https://doi.org/10.3892/or.2019.7259
MLA
Tong, J., Shen, Y., Chen, X., Wang, R., Hu, Y., Zhang, X., Zhang, Z., Han, L."FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression". Oncology Reports 42.4 (2019): 1404-1412.
Chicago
Tong, J., Shen, Y., Chen, X., Wang, R., Hu, Y., Zhang, X., Zhang, Z., Han, L."FKBP3 mediates oxaliplatin resistance in colorectal cancer cells by regulating HDAC2 expression". Oncology Reports 42, no. 4 (2019): 1404-1412. https://doi.org/10.3892/or.2019.7259